Type 2 Diabetes Mellitus Clinical Trial
Official title:
Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin
Management of type 2 diabetes is an ongoing challenge for patients and their doctors. In order to prevent complications, patients need to monitor and control their blood sugar levels. In addition, they may need to have an ongoing communication with their doctor in order to modify treatment. In this study the investigators wish to compare the benefits of continuous glucose monitoring system (CGMS) to an internet-based glucose monitoring system (IBGMS). The investigators also want to determine whether the frequency of blood glucose testing affects blood glucose control and to see whether the benefits of CGMS and IBGMS are independent of testing frequency.
In this current study, the investigators wish to test several hypotheses: whether the
frequency of SMBG is correlated with HbA1c, whether the knowledge that strips are being
counted affects HbA1c, whether the reduction of HbA1c when using an IBGMS is independent of
the frequency of testing, and whether there is a difference between IBGMS and CGMS in HbA1c
reduction.
The investigators will recruit 100 patients with type 2 diabetes who satisfy the
inclusion/exclusion criteria. For the first visit, the patients will be immediately
randomized into four groups. One group will be testing 3 times a day (SMBG). The second
group will be similar to the SMBG group except they will know that we are counting the
frequency of testing (SMBG With Knowledge). The third group will use an IBGMS and the fourth
group will use a CGMS. During the first visit, we will teach the patient how to use the
programs and machinery for their group. All four groups will be asked to follow the protocol
and to visit their doctor in 3 month intervals for 6 months along with completed laboratory
blood test results.
For the SMBG and the SMBG With Knowledge group, each will be given a new meter and be asked
to test 3 times a day. They will also be required to keep a diary of their SMBG levels. The
difference between the two is that the SMBG With Knowledge group will know that we are
counting strips. The SMBG group will believe that we are testing a new meter and will not
know that the SMBG With Knowledge group exists. This deception is necessary to test the
experimental effect of if the patient knows that we are counting the frequency of testing,
does that affect the frequency that they are testing. The investigators will tell the SMBG
group that we are testing the accuracy of a new meter and they should test 3 times a day.
For the CGMS and IBGMS group, they will also be counting the frequency of blood glucose
testing to see whether the benefits from both are independent of the number of tests.
Furthermore, we wish to compare the these two methods of blood glucose monitoring. Both
groups will have to upload their data onto the internet and communicate with their doctor
every 2 weeks using a secure online web site.
At the end of 3 and 6 months, we will collect the frequency of testing from each group to
determine whether increased glycemic control correlates with increased testing. We will also
collect their SMBG diaries to see whether the written data correlates with the data on their
meter. The investigators will also be comparing a measure of their blood glucose levels for
each group and determining the effectiveness of CGMS and IBGMS.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |